Sarepta Therapeutics | SRPT - Ativos





Ativos Alterar Data
Acadia Pharmaceuticals USD 1.56B 233.42M 2025-12
Agios Pharmaceuticals USD 1.18B 112.24M 2026-03
Alnylam Pharmaceuticals USD 4.97B 114.67M 2025-12
Amgen USD 90.59B 445M 2025-12
BioCryst Pharmaceuticals USD 514.16M 67.73M 2025-12
Biogen USD 29.48B 43.6M 2026-03
BioMarin Pharmaceutical USD 7.59B 20.85M 2025-12
Capricor Therapeutics USD 355.95M 229.51M 2025-12
Daiichi Sankyo JPY 3.82T 252.52B 2025-12
Eli Lilly USD 112.48B 2.46B 2025-12
Esperion Therapeutics USD 465.89M 101.87M 2025-12
Gilead Sciences USD 59.02B 490M 2025-12
Incyte USD 7.34B 381.14M 2026-03
Insmed USD 2.26B 96.18M 2025-12
Ionis Pharmaceuticals USD 3.45B 74M 2026-03
Moderna USD 12.34B 203M 2025-12
Nektar Therapeutics USD 280.41M 20.94M 2025-12
Neurocrine Biosciences USD 4.63B 365.8M 2025-12
Novavax USD 1.18B 3.38M 2025-12
Pfizer USD 208.73B 2.64B 2025-09
PTC Therapeutics USD 2.9B 255.07M 2025-12
Regeneron Pharmaceuticals USD 40.87B 310.1M 2026-03
Roche Holding CHF 100.7B 5.94B 2025-12
Sangamo BioSciences USD 97.56M 11.39M 2025-06
Sanofi EUR 128.02B 1.22B 2026-03
Sarepta Therapeutics USD 3.35B 143.73M 2025-12
Tectonic Therapeutic USD 261.04M 15.96M 2025-12
Ultragenyx Pharmaceutical USD 1.53B 341.56M 2025-12
Vertex Pharmaceuticals USD 25.64B 780.7M 2025-12